Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630038 | 1.00 | IRAK4 (0.39) | IRAK4PRKCQPRKCDBACE1BACE2 | |
| SCHEMBL29740094 | 1.00 | IRAK4 (0.39) | IRAK4PRKCQPRKCDBACE1BACE2 | |
| SCHEMBL19866882 | 0.82 | PRKCQ (0.44) | IRAK4PRKCQPRKCDCHUK | |
| SCHEMBL30379722 | 0.82 | PRKCQ (0.44) | IRAK4PRKCQPRKCDCHUK | |
| SCHEMBL19630089 | 0.81 | KDM4E (0.42) | PRKCQPRKCD | |
| SCHEMBL21346353 | 0.81 | KDM4E (0.42) | PRKCQPRKCD | |
| SCHEMBL20749043 | 0.81 | KDM4E (0.42) | PRKCQPRKCD | |
| SCHEMBL20740396 | 0.81 | KDM4E (0.42) | PRKCQPRKCD | |
| SCHEMBL19629939 | 0.81 | KDM4E (0.42) | PRKCQPRKCD | |
| SCHEMBL19629977 | 0.81 | KDM4E (0.42) | PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | IRAK4 1576/4885PRKCQ 3152/4885PRKCD 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.